Browse > Article
http://dx.doi.org/10.1038/s12276-018-0175-1

Selective blockade of spinal D2DR by levo-corydalmine attenuates morphine tolerance via suppressing PI3K/Akt-MAPK signaling in a MOR-dependent manner  

Dai, Wen-Ling (Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University)
Liu, Xin-Tong (School of Life Science and Technology, China Pharmaceutical University)
Bao, Yi-Ni (Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University)
Yan, Bing (Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University)
Jiang, Nan (Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University)
Yu, Bo-Yang (State Key Laboratory of Natural Medicines, China Pharmaceutical University)
Liu, Ji-Hua (Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University)
Publication Information
Experimental and Molecular Medicine / v.50, no.11, 2018 , pp. 6.1-6.12 More about this Journal
Abstract
Morphine tolerance remains a challenge in the management of chronic pain in the clinic. As shown in our previous study, the dopamine D2 receptor (D2DR) expressed in spinal cord neurons might be involved in morphine tolerance, but the underlying mechanisms remain to be elucidated. In the present study, selective spinal D2DR blockade attenuated morphine tolerance in mice by inhibiting phosphatidylinositol 3 kinase (PI3K)/serine-threonine kinase (Akt)-mitogen activated protein kinase (MAPK) signaling in a ${\mu}$ opioid receptor (MOR)-dependent manner. Levo-corydalmine (l-CDL), which exhibited micromolar affinity for D2DR in D2/CHO-K1 cell lines in this report and effectively alleviated bone cancer pain in our previous study, attenuated morphine tolerance in rats with chronic bone cancer pain at nonanalgesic doses. Furthermore, the intrathecal administration of l-CDL obviously attenuated morphine tolerance, and the effect was reversed by a D2DR agonist in mice. Spinal D2DR inhibition and l-CDL also inhibited tolerance induced by the MOR agonist DAMGO. l-CDL and a D2DR small interfering RNA (siRNA) decreased the increase in levels of phosphorylated Akt and MAPK in the spinal cord; these changes were abolished by a PI3K inhibitor. In addition, the activated Akt and MAPK proteins in mice exhibiting morphine tolerance were inhibited by a MOR antagonist. Intrathecal administration of a PI3K inhibitor also attenuated DAMGO-induced tolerance. Based on these results, l-CDL antagonized spinal D2DR to attenuate morphine tolerance by inhibiting PI3K/Akt-dependent MAPK phosphorylation through MOR. These findings provide insights into a more versatile treatment for morphine tolerance.
Keywords
Citations & Related Records
연도 인용수 순위
  • Reference
1 Matthes, H. W. et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383, 819-823 (1996).   DOI
2 Le Merrer, J., Becker, J. A., Befort, K. & Kieffer, B. L. Reward processing by the opioid system in the brain. Physiol. Rev. 89, 1379-1412 (2009).   DOI
3 Dang, V. C., Chieng, B., Azriel, Y. & Christie, M. J. Cellular morphine tolerance produced by betaarrestin-2-dependent impairment of mu-opioid receptor resensitization. J. Neurosci. 31, 7122-7130 (2011).   DOI
4 Bohn, L. M. et al. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286, 2495-2498 (1999).   DOI
5 Raehal, K. M. & Bohn, L. M. The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology 60, 58-65 (2011).   DOI
6 Klewe, I. V. et al. Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling. Neuropharmacology 54, 1215-1222 (2008).   DOI
7 Basu, D. et al. Effects of the dopamine D2 allosteric modulator, PAOPA, on the expression of GRK2, arrestin-3, ERK1/2, and on receptor internalization. PLoS One 8, e70736 (2013).   DOI
8 Wang, J. et al. miR-365 targets beta-arrestin 2 to reverse morphine tolerance in rats. Sci. Rep. 6, 38285 (2016).   DOI
9 Xu, J. T. et al. Opioid receptor-triggered spinal mTORC1 activation contributes to morphine tolerance and hyperalgesia. J. Clin. Invest. 124, 592-603 (2014).   DOI
10 Khan, S. M. et al. The expanding roles of Gbetagamma subunits in G proteincoupled receptor signaling and drug action. Pharmacol. Rev. 65, 545-577 (2013).   DOI
11 Nair, V. D. & Sealfon, S. C. Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D2 receptor. J. Biol. Chem. 278, 47053-47061 (2003).   DOI
12 Chen, Y. & Sommer, C. The role of mitogen-activated protein kinase (MAPK) in morphine tolerance and dependence. Mol. Neurobiol. 40, 101-107 (2009).   DOI
13 Steelman, L. S. et al. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18, 189-218 (2004).   DOI
14 Narkar, V. A., Hussain, T., Pedemonte, C. & Lokhandwala, M. F. Dopamine D(2) receptor activation causes mitogenesis via p44/42 mitogen-activated protein kinase in opossum kidney cells. J. Am. Soc. Nephrol. 12, 1844-1852 (2001).
15 Advokat, C. Tolerance to the antinociceptive effect of morphine in spinally transected rats. Behav. Neurosci. 103, 1091-1098 (1989).   DOI
16 Lai, E. C., Hsieh, C. Y., Kao Yang, Y. H. & Lin, S. J. Detecting potential adverse reactions of sulpiride in schizophrenic patients by prescription sequence symmetry analysis. PLoS One 9, e89795 (2014).   DOI
17 Noori-Daloii, M. R. et al. Use of siRNA in knocking down of dopamine receptors, a possible therapeutic option in neuropsychiatric disorders. Mol. Biol. Rep. 39, 2003-2010 (2012).   DOI
18 Inturrisi, C. E. Clinical pharmacology of opioids for pain. Clin. J. Pain. 18, S3-S13 (2002).   DOI
19 Hu, Y. et al. Levo-corydalmine alleviates neuropathic cancer pain induced by tumor compression via the CCL2/CCR2 pathway. Molecules 22, 937 (2017).   DOI
20 Kreek, M. J. Drug addictions. Molecular and cellular endpoints. Ann. N. Y. Acad. Sci. 937, 27-49 (2001).
21 Hutchinson, M. R. et al. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol. Rev. 63, 772-810 (2011).   DOI
22 Williams, J. T. et al. Regulation of ${\mu}$-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol. Rev. 65, 223-254 (2013).   DOI
23 He, S. Q. et al. Facilitation of mu-opioid receptor activity by preventing deltaopioid receptor-mediated codegradation. Neuron 69, 120-131 (2011).   DOI
24 Nair, V. D., Olanow, C. W. & Sealfon, S. C. Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem. J. 373, 25-32 (2003).   DOI
25 Zhou, L. et al. Levo-corydalmine alleviates vincristine-induced neuropathic pain in mice by inhibiting an NF-kappa B-dependent CXCL1/CXCR2 signaling pathway. Neuropharmacology 135, 34-47 (2018).   DOI
26 Trescot, A. M., Datta, S., Lee, M. & Hansen, H. Opioid pharmacology. Pain Physician 11, S133-S153 (2008).
27 Yang, C. H. et al. Antinociceptive potentiation and attenuation of tolerance by intrathecal beta-arrestin 2 small interfering RNA in rats. Br. J. Anaesth. 107, 774-781 (2011).   DOI
28 Beaulieu, J. M. & Gainetdinov, R. R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 63, 182-217 (2011).   DOI
29 Tian, Y. et al. Early single aspirin-triggered Lipoxin blocked morphine antinociception tolerance through inhibiting NALP1 inflammasome: involvement of PI3k/Akt signaling pathway. Brain Behav. Immun. 50, 63-77 (2015).   DOI
30 Melik Parsadaniantz, S., Rivat, C., Rostene, W. & Reaux-Le Goazigo, A. Opioid and chemokine receptor crosstalk: a promising target for pain therapy? Nat. Rev. Neurosci. 16, 69-78 (2015).
31 Zhou, D., Chen, M. L., Zhang, Y. Q. & Zhao, Z. Q. Involvement of spinal microglial P2X7 receptor in generation of tolerance to morphine analgesia in rats. J. Neurosci. 30, 8042-8047 (2010).   DOI
32 Ji, R. R. Targeting microglial purinergic signaling to improve morphine analgesia. Pain 150, 377-378 (2010).   DOI
33 Wei, H., Viisanen, H. & Pertovaara, A. Descending modulation of neuropathic hypersensitivity by dopamine D2 receptors in or adjacent to the hypothalamic A11 cell group. Pharmacol. Res. 59, 355-363 (2009).   DOI
34 Eidson, L. N. & Murphy, A. Z. Persistent peripheral inflammation attenuates morphine-induced periaqueductal gray glial cell activation and analgesic tolerance in the male rat. J. Pain 14, 393-404 (2013).   DOI
35 Ferrini, F. et al. Morphine hyperalgesia gated through microglia-mediated disruption of neuronal Cl-homeostasis. Nat. Neurosci. 16, 183-192 (2013).   DOI
36 Von Willebrand, M. et al. Inhibition of phosphatidylinositol 3-kinase blocks T cell antigen receptor/CD3-induced activation of the mitogen-activated kinase Erk2. Eur. J. Biochem. 235, 828-835 (1996).   DOI
37 Shen, N. et al. A novel role of spinal astrocytic connexin 43: mediating morphine antinociceptive tolerance by activation of NMDA receptors and inhibition of glutamate transporter-1 in rats. CNS Neurosci. Ther. 20, 728-736 (2014).   DOI
38 Luo, C., Kuner, T. & Kuner, R. Synaptic plasticity in pathological pain. Trends Neurosci. 37, 343-355 (2014).   DOI
39 Sheng, H. Y., Qu, C. L., Huo, F. Q., Du, J. Q. & Tang, J. S. D2-like but not D1-like dopamine receptors are involved in the ventrolateral orbital cortex-induced antinociception: a GABAergic modulation mechanism. Exp. Neurol. 215, 128-134 (2009).   DOI
40 Shamsizadeh, A. et al. Involvement of dopamine receptors within the dorsal hippocampus in suppression of the formalin-induced orofacial pain. Pharmacol. Biochem. Behav. 114-115, 37-42 (2013).   DOI
41 Verma, A. & Kulkarni, S. Role of D 1/D 2 dopamine and N-methyl-d-aspartate (NMDA) receptors in morphine tolerance and dependence in mice. Eur. Neuropsychopharm. 5, 81-87 (1995).   DOI
42 Cross, D. A. E. et al. The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle Cell Line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf. Biochem. J. 303, 21-26 (1994).   DOI
43 Conway, A. M., Rakhit, S., Pyne, S. & Pyne, N. J. Platelet-derived-growth-factor stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle: role of pertussis-toxin-sensitive G-proteins, c-Src tyrosine kinases and phosphoinositide 3-kinase. Biochem. J. 337, 171-177 (1999).   DOI
44 King, M. A., Bradshaw, S., Chang, A. H., Pintar, J. E. & Pasternak, G. W. Potentiation of opioid analgesia in dopamine2 receptor knock-out mice: evidence for a tonically active anti-opioid system. J. Neurosci. 21, 7788-7792 (2001).   DOI
45 Zarrindast, M. R., Dinkoub, Z., Homayoun, H., Bakhtiarian, A. & Khavandgar, S. Dopamine receptor mechanism (s) and morphine tolerance in mice. J. Psychopharmacol. 16, 261-266 (2002).   DOI
46 Ozdemir, E., Bagcivan, I. & Gursoy, S. Role of D(1)/D(2) dopamin receptors antagonist perphenazine in morphine analgesia and tolerance in rats. Bosn. J. Basic. Med. Sci. 13, 119-125 (2013).   DOI
47 Xiao, W. et al. Characterization of human metabolism and disposition of levotetrahydropalmatine: qualitative and quantitative determination of oxidative and conjugated metabolites. J. Pharm. Biomed. Anal. 128, 371-381 (2016).   DOI
48 Ferby, I. M., Waga, I., Hoshino, M., Kume, K. & Shimizu, T. Wortmannin inhibits mitogen-activated protein kinase activation by platelet-activating factor through a mechanism independent of p85/p110-type phosphatidylinositol 3-kinase. J. Biol. Chem. 271, 11684-11688 (1996).   DOI
49 Dai, W. L. et al. Blockade of neuronal dopamine D2 receptor attenuates morphine tolerance in mice spinal cord. Sci. Rep. 6, 38746 (2016).   DOI
50 Dai, W. L. et al. Simultaneous inhibition of NMDA and mGlu1/5 receptors by levo-corydalmine in rat spinal cord attenuates bone cancer pain. Int. J. Cancer 141, 805-815 (2017).   DOI
51 Parraga, J. et al. 2,3,9- and 2,3,11-trisubstituted tetrahydroprotoberberines as D2 dopaminergic ligands. Eur. J. Med. Chem. 68, 150-166 (2013).   DOI
52 Stone, L. S., MacMillan, L. B., Kitto, K. F., Limbird, L. E. & Wilcox, G. L. The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy. J. Neurosci. 17, 7157-7165 (1997).   DOI
53 Sun, H. et al. Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile. Bioorg. Med Chem. 21, 856-868 (2013).   DOI
54 Njoo, C., Heinl, C. & Kuner, R. In vivo SiRNA transfection and gene knockdown in spinal cord via rapid noninvasive lumbar intrathecal injections in mice. J. Vis. Exp. 22, e51229 (2014).
55 Gong, N., Fan, H., Ma, A. N., Xiao, Q. & Wang, Y. X. Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors. Neuropharmacology 84, 31-45 (2014).   DOI
56 Bradman, M. J., Ferrini, F., Salio, C. & Merighi, A. Practical mechanical threshold estimation in rodents using von Frey hairs/Semmes-Weinstein monofilaments: towards a rational method. J. Neurosci. Methods 255, 92-103 (2015).   DOI
57 Zhang, Y. et al. A novel analgesic isolated from a traditional Chinese medicine. Curr. Biol. 24, 117-123 (2014).   DOI
58 Wu, X. F. et al. Reopening of ATP-sensitive potassium channels reduces neuropathic pain and regulates astroglial gap junctions in the rat spinal cord. Pain 152, 2605-2615 (2011).   DOI